The content on this site is intended for healthcare professionals only
Trial results at ASH 2013
Rituximab maintenance therapy and CLL treatment considerations going forward
Meeting the needs of the elderly, unfit CLL patient
Improving outcomes in chronic lymphocytic leukaemia
Where next for chronic lymphocytic leukaemia in the elderly?
A new trial alters therapy landscape in multiple myeloma
Where to next for the elderly with acute myeloid leukaemia?
Exciting new developments in the treatment of multicentric Castleman disease
New therapy aspects for myeloid chronic lymphoma
Encouraging early results with GS-9973 for CLL and NHL
Role of Bcl-2 family in lymphoid malignancies
FLT3-ITD positive acute myeloid leukaemia
PI3K-delta inhibitor idelalisib success in CLL
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma
T cell immunotherapy for leukaemia in preclinical setting
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL)
Gemtuzumab improves event free survival for paediatric acute myeloid leukaemia (AML)
Comment: Transplantation and short telomeres increase the risk of cognitive impairment
Equality of access to transplant for ethnic minority patients
New agents in CLL
Full-intensity transplantation and short telomeres increase risk of cognitive impairment after allogeneic haematopoietic cell transplantation
Targeting tyrosine kinase receptors to tackle CML
Chronic lymphocytic leukaemia: A new treatment era is born
Chemo-free treatment for acute promyelocytic leukaemia
Initial phase III results of the first trial in newly diagnosed multiple myeloma
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3
Treating ALL patients with T cells targeted for CD19
Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies
T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence
Removal of alpha/beta T cells and of CD19 B cells in children With acute leukaemia
Transplantation and short telomeres increase the risk of cognitive impairment
Results from the randomised phase III Children’s Oncology Group (COG) trial, AAML0531
In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist
Final stage II results of the CLL11 trial
Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease
Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy
Equality of access to transplant for ethnic minority patients
Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma
Encouraging outcomes in older patients following nonmyeloablative haploidentical blood or marrow transplantation
Immune reconstitution and preliminary safety analysis of somatic gene therapy
